Technological offer

Penicillium strain that produces a highly active antifungal protein (AFP), namely PeAfpA, which is effective against pathogenic and food spoilage fungi. The strain has also been modified to eliminate its antibiotic resistance genes, ensuring its safe use in agriculture, food, and biomedical applications.

New compounds to treat parasitic diseases such as Chagas disease, leishmaniasis and trypanosomiasias. These derivatives act on a new target: G-cuadruplex DNA

New antiviral compound against HSV-1 and HSV-2 that can be used in combination with other drugs or to treat resistant strains to conventional antivirals.

Stratum corneum lipid-matrix like liposomes capable of acting as oral mucosa impermeabilization agents to prevent the penetration of viruses or biocides through the mucosa.

New nanostructured lipid carriers have demonstrated inhibition of bacterial biofilm formation. They are useful for treating or preventing chronic infections such as those associated with prosthetic implants and recurrent respiratory infections.

Novel compounds based on a repurposed drug to combat gram (+) bacterial infections.

Novel DNA probes useful for the rapid detection of SARS-CoV2, influenza and respiratory syncytial viral RNAs. Integrated in different set of devices, these probes enable the detection of RNA sequences in few minutes, without the need for RNA extraction, purification and PCR amplification

Novel antiviral strategy targeting viral non-essential proteins (NEPs), scarcely prone to adaptive mutations. As a proof of concept, SARS-CoV-2 ORF9b homodimerization inhibitors have been identified that prevents the virus hyperinflammation response.

Polysaccharides, mimics of heparan sulfates present in cells, that are effective in treatment and prevention of viral infections. They act as a decoy trap to prevent the virus from adhering to epithelial cells, thus slowing down the process of infection, and by directly inactivating the viral particles.

Two different vaccines prototypes have been developed based on RNA replicons from SARS-CoV-2 and MERS-CoV, encapsulated in Virus-Like Particles (VLPs), which can be used as a vaccines to generate immunity and protect against infections by these coronavirus.